STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
An announcement from Cytosorbents Corp (CTSO) is now available. CytoSorbents Corporation has launched a voluntary salary reduction program as a cost-saving measure, with top executives including the CEO and CFO
Analyst Sean Lee CFA of H.C. Wainwright maintained a Hold rating on Cytosorbents (CTSO – Research Report), with a price target of $1.00. Sean Lee CFA’s rating is based on
The increase in the average Euro to U.S. dollar exchange rate favorably impacted Q4 product sales by approximately $0.4M. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “In 2024, we
Reports FY23 revenue $31.02M, consensus $36.94M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >>